Zimmer Biomet Holdings Inc (ZBH) Shares Sold by Trillium Asset Management LLC

Trillium Asset Management LLC lowered its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 11.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 4,763 shares of the medical equipment provider’s stock after selling 603 shares during the quarter. Trillium Asset Management LLC’s holdings in Zimmer Biomet were worth $608,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Nisa Investment Advisors LLC raised its stake in shares of Zimmer Biomet by 5.5% in the first quarter. Nisa Investment Advisors LLC now owns 85,539 shares of the medical equipment provider’s stock valued at $10,923,000 after purchasing an additional 4,496 shares in the last quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO raised its stake in Zimmer Biomet by 100.0% during the fourth quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 3,306 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 1,653 shares in the last quarter. LaFleur & Godfrey LLC raised its stake in Zimmer Biomet by 8.8% during the first quarter. LaFleur & Godfrey LLC now owns 36,320 shares of the medical equipment provider’s stock worth $4,638,000 after acquiring an additional 2,935 shares in the last quarter. Dubuque Bank & Trust Co. acquired a new position in Zimmer Biomet during the first quarter worth $84,000. Finally, FNY Investment Advisers LLC acquired a new position in Zimmer Biomet during the first quarter worth $54,000. 89.40% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet stock traded down $0.70 during mid-day trading on Friday, hitting $117.38. The stock had a trading volume of 20,612 shares, compared to its average volume of 1,241,325. The stock has a market cap of $24.28 billion, a price-to-earnings ratio of 15.40, a P/E/G ratio of 2.18 and a beta of 1.19. Zimmer Biomet Holdings Inc has a 12 month low of $96.99 and a 12 month high of $134.55. The company has a quick ratio of 0.97, a current ratio of 2.00 and a debt-to-equity ratio of 0.72.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Friday, April 26th. The medical equipment provider reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.01. The business had revenue of $1.98 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Zimmer Biomet had a positive return on equity of 13.24% and a negative net margin of 3.90%. The firm’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same quarter last year, the business earned $1.91 earnings per share. As a group, sell-side analysts expect that Zimmer Biomet Holdings Inc will post 7.81 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 30th. Investors of record on Friday, March 29th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.82%. The ex-dividend date was Thursday, March 28th. Zimmer Biomet’s dividend payout ratio is 12.57%.

In other news, Director Syed A. Jafry purchased 1,925 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were acquired at an average price of $125.52 per share, for a total transaction of $241,626.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.72% of the stock is owned by company insiders.

A number of analysts have recently weighed in on the company. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Saturday, April 13th. Barclays raised their target price on Zimmer Biomet from $113.00 to $117.00 and gave the company an “underweight” rating in a research note on Monday, April 15th. Evercore ISI upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $145.00 target price for the company in a research note on Monday, April 8th. Morgan Stanley raised their target price on Zimmer Biomet from $132.00 to $143.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Finally, Cantor Fitzgerald set a $135.00 target price on Zimmer Biomet and gave the company a “buy” rating in a research note on Friday, April 26th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $130.19.

TRADEMARK VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2019/05/17/zimmer-biomet-holdings-inc-zbh-shares-sold-by-trillium-asset-management-llc.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: The primary rules of Elliott Wave theory

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.